Latest Recruitment News

Metro Mining has reset its 2026 bauxite shipment guidance to 6.0-6.5 million wet metric tonnes after September performance fell below plan. The company is relying on channel repairs, stronger staffing and a drier weather outlook to recover shipments before its February maintenance shutdown.

Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.

Latrobe Magnesium says its Phase 1B demonstration plant is 95% installed and 35% commissioned, keeping first magnesium metal crowns above 98% purity on track for the end of 2026. The operational advance comes alongside a tight funding position, an extended A$3.4 million entitlement offer and an ambitious South Carolina expansion plan.

Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.

EDU Holdings has lifted total enrolments 26% to a record 7,489, with Higher Education up 45% and now accounting for 88% of the group. The result also exposes a sharper divide: domestic and postgraduate demand is strengthening, while international VET enrolments continue to contract.

Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.

Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.

DGL Group’s FY26 annual report lays bare a difficult year: revenue and underlying earnings fell, statutory losses widened and the auditor issued a qualified opinion over opening inventory. Management is betting on cost cuts, fuller facilities and a new liquid waste plant to repair performance in FY27.

Arovella Therapeutics has released a second clinical batch of its off-the-shelf CAR-iNKT therapy ALA-101, with material expected to support dose escalation and the start of dose expansion in blood cancers. The company is also adding hospital sites ahead of anticipated first-patient dosing in late October.

Toubani Resources says construction of its Kobada Gold Project in Mali remains on schedule for first gold in Q3 2027, with CIL tank erection now underway and more than 70% of project costs committed. About US$50 million of the company’s US$160 million stream facility has been drawn as construction moves into a more intensive phase.

Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.